Based on the BeyondSpring Inc stock forecast from 0 analysts, the average analyst target price for BeyondSpring Inc is not available over the next 12 months. BeyondSpring Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BeyondSpring Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, BeyondSpring Inc’s stock price was USD 1.36. BeyondSpring Inc’s stock price has changed by +12.40% over the past week, -15.00% over the past month and -40.61% over the last year.
No recent analyst target price found for BeyondSpring Inc
No recent average analyst rating found for BeyondSpring Inc
Company Overview BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey. Read Less
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical ...Read More
Frequently Asked Questions About BeyondSpring Inc (BYSI) Stock
Stock Target Advisor's fundamental analysis for BeyondSpring Inc's stock is Bearish.
Unfortunately we do not have enough data on BYSI's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BYSI's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BYSI's stock to indicate if its overvalued.
The last closing price of BYSI's stock was USD 1.36.
The most recent market capitalization for BYSI is USD 0.07B.
Unfortunately we do not have enough analyst data on BYSI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BeyondSpring Inc's stock.
As per our most recent records BeyondSpring Inc has 40 Employees.
BeyondSpring Inc's registered address is 100 Campus Drive, Florham Park, NJ, United States, 07932.
You can get more information about it from BeyondSpring Inc's website at https://beyondspringpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About BeyondSpring Inc (BYSI) Stock
Stock Target Advisor's fundamental analysis for BeyondSpring Inc's stock is Bearish.
Unfortunately we do not have enough data on BYSI's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BYSI's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BYSI's stock to indicate if its overvalued.
The last closing price of BYSI's stock was USD 1.36.
The most recent market capitalization for BYSI is USD 0.07B.
Unfortunately we do not have enough analyst data on BYSI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BeyondSpring Inc's stock.
As per our most recent records BeyondSpring Inc has 40 Employees.
BeyondSpring Inc's registered address is 100 Campus Drive, Florham Park, NJ, United States, 07932.
You can get more information about it from BeyondSpring Inc's website at https://beyondspringpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BYSI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
